uniQure Investors Face April 13 Deadline in Securities Class Action Over FDA Setback
Prospective lead plaintiffs must ask the SDNY to be appointed by April 13 in the case tied to the company’s Huntington’s therapy data dispute.
Overview
- Scocco v. uniQure N.V., Case No. 1:26-cv-01124, is pending in the U.S. District Court for the Southern District of New York.
- The putative class covers purchases of uniQure ordinary shares between September 24, 2025 and October 31, 2025.
- The complaint alleges investors were misled about whether the AMT-130 Pivotal Study’s design—relying on ENROLL-HD external controls—had full FDA buy-in.
- On November 3, 2025, uniQure disclosed the FDA no longer agreed that Phase I/II external-control data may be adequate for a BLA, and the stock fell about 49% that day.
- Kessler Topaz Meltzer & Check, Kirby McInerney, and Kahn Swick & Foti are soliciting investors and highlighting the April 13, 2026 lead-plaintiff deadline.